MAPT and Alzheimer disease: In this study, we evaluated the ability of baseline CSF sTREM2, PGRN, p-tau181, Aβ42/40, t-tau, brain volumes, and plasma β amyloid deposition, pathologic tau, and neurodegeneration [AT(N)] biomarkers to predict the longitudinal cognitive deterioration in subjects with positive AD pathology.